Reminder: Portola Pharmaceuticals to Host Webcast and Conference Call Today, Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch

Tuesday, September 5, 2017 12:01 PM UTC

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 -- Portola Pharmaceuticals (Nasdaq:PTLA) announced that it will host a webcast and conference call to provide an update on Bevyxxa^®(betrixaban) launch plans, the validation of the commercial manufacturing process and drug release timing.

Conference Call Details
The live conference call today, Tuesday, September 5, 2017, at 4:30 p.m. Eastern Time (1:30 p.m. PT)., can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765)-507-2588 internationally and using the passcode 75259872. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa^® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.

Investor Contact:                                       
Michele Mantynen                                       
Portola Pharmaceuticals                            
[email protected]                                         

Media Contact:
Jacquelyn Matter
Pure Communications
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Reminder: Portola Pharmaceuticals to Host Webcast and Conference Call Today, Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch

Editor's Picks

Welcome to EconoTimes